Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | PKLR | P30613 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6370683 | 0.85 | NUDT1 (0.42) | NUDT1SSTR4L3MBTL1KMT2ATNKS | |
| SCHEMBL2658224 | 0.77 | NUDT1 (0.36) | NUDT1L3MBTL1TNKS | |
| SCHEMBL259658 | 0.77 | NUDT1 (0.42) | NUDT1HSD11B1L3MBTL1KMT2AMEN1 | |
| SCHEMBL15038308 | 0.76 | FDPS (0.36) | NUDT1SSTR4HTR2A | |
| SCHEMBL28397476 | 0.74 | SSTR4 (0.39) | NUDT1HSD11B1SSTR4KMT2ATNKS | |
| SCHEMBL21245955 | 0.73 | SSTR4 (0.39) | NUDT1SSTR4L3MBTL1TNKSPKLR | |
| SCHEMBL1041231 | 0.72 | NUDT1 (0.45) | NUDT1SSTR4L3MBTL1HTR2A | |
| SCHEMBL259019 | 0.72 | L3MBTL1 (0.48) | NUDT1SSTR4L3MBTL1TNKS | |
| SCHEMBL18342232 | 0.72 | NUDT1 (0.41) | NUDT1SSTR4L3MBTL1KMT2AMEN1 | |
| SCHEMBL21334961 | 0.71 | NUDT1 (0.37) | NUDT1SSTR4L3MBTL1KMT2ATNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401274-B1 | IMIDAZO[1,2-A]PYRIDINES AS JNK MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-10-22 | — | — | EP | disclosed |
| US-8569306-B2 | JNK modulators | HOFFMANN-LA ROCHE, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| CN-102325771-A | Imidazo [1,2-A ] pyridines as JNK modulators | HOFFMANN LA ROCHE | 2012-01-18 | — | — | CN | disclosed |
| EP-2401274-A1 | IMIDAZO [1, 2 -A]PYRIDINES AS JNK MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| US-20110306618-A1 | JNK Modulators | BUETTELMANN BERND (DE) | 2011-12-15 | — | — | US | disclosed |
| WO-2010097335-A1 | IMIDAZO [1, 2 -A] PYRIDINES AS JNK MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306618-A1 | JNK Modulators | MAPK3, MAPK1, MAPK4 | NUDT1 4664/4885HSD11B1 972/4885SSTR4 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.